These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 11313303

  • 1. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
    Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G, German ICAM-1 Study Group.
    Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
    Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR.
    Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
    Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E.
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
    [Abstract] [Full Text] [Related]

  • 8. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
    Kahan BD, Stepkowski S, Kilic M, Katz SM, Van Buren CT, Welsh MS, Tami JA, Shanahan WR.
    Transplantation; 2004 Sep 27; 78(6):858-63. PubMed ID: 15385805
    [Abstract] [Full Text] [Related]

  • 9. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
    Yacyshyn B, Bowen-Yacyshyn MB, Shanahan W.
    Curr Opin Mol Ther; 1999 Jun 27; 1(3):332-5. PubMed ID: 11713798
    [Abstract] [Full Text] [Related]

  • 10. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT, Sitaraman S.
    Curr Opin Investig Drugs; 2001 Oct 27; 2(10):1401-6. PubMed ID: 11890355
    [Abstract] [Full Text] [Related]

  • 11. ISIS 2302. Oligo-TCS.
    Drugs R D; 1999 Mar 27; 1(3):265-7. PubMed ID: 10566042
    [No Abstract] [Full Text] [Related]

  • 12. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J.
    Clin Cancer Res; 2000 May 27; 6(5):1626-31. PubMed ID: 10815879
    [Abstract] [Full Text] [Related]

  • 13. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR.
    J Pharmacol Exp Ther; 1997 Sep 27; 282(3):1173-80. PubMed ID: 9316823
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ISIS 2302. INXC ICAM1, Oligo-TCS.
    Drugs R D; 1999 Jan 27; 1(1):85-6. PubMed ID: 10565996
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Technology evaluation: alicaforsen (Isis).
    Gewirtz AT, Sitaraman SV.
    Curr Opin Mol Ther; 2005 Jun 27; 7(3):273-81. PubMed ID: 15977426
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D, Macdonald JK, Chande N.
    Cochrane Database Syst Rev; 2014 Feb 21; (2):CD010410. PubMed ID: 24558033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.